TABLE 2.
Antibiotic(s) | Isolate(s) | NCCLS breakpoints (mm) | No. tested | SIc/SIsa | Rc/Rsb | SIc/Rsc | Rc/SIsd | Zone size(s) (mm) of Rc/SIs isolate(s)e | % of results that were very major errorsf |
---|---|---|---|---|---|---|---|---|---|
Amoxicillin-clavulanate | Staphylococcus sp. | ≥20 | 127 | 102 | 19 | 1 | 5 | 20 (S), 20 (S), 20 (S), 21 (S), 22 (S) | 3.9 |
Gram-negative bacilli | 14–17 | 87 | 73 | 14 | 0 | 0 | |||
Ampicillin | Gram-negative bacilli | 14–16 | 209 | 87 | 122 | 0 | 0 | ||
Aztreonam | Gram-negative bacilli | 16–21 | 241 | 219 | 18 | 0 | 4 | 16 (I), 17 (I), 17 (I), 17 (I) | |
Cefotaxime | Gram-negative bacilli | 15–22 | 209 | 197 | 10 | 1 | 1 | 15 (I) | |
Cefuroxime sodium | Gram-negative bacilli | 15–17 | 209 | 171 | 37 | 0 | 1 | 18 (S) | 0.5 |
Cephalothin | Gram-negative bacilli | 15–17 | 210 | 128 | 75 | 7 | 0 | ||
Ciprofloxacin | Gram-negative bacilli and Staphylococcus sp. | 16–20 | 278 | 221 | 56 | 0 | 1 | 17 (I) | |
Clindamycin | Staphylococcus sp. | 15–20 | 127 | 99 | 28 | 0 | 0 | ||
Erythromycin | Staphylococcus sp. | 14–22 | 127 | 46 | 79 | 0 | 2 | 14 (I), 14 (I) | |
Gentamicin | Gram-negative bacilli and Staphylococcus sp. | 13–14 | 364 | 326 | 35 | 1 | 2 | 14 (I), 14 (I) | |
Imipenem | Gram-negative bacilli | 14–15 | 241 | 233 | 8 | 0 | 0 | ||
Mezlocillin | Pseudomonas sp. | ≥16 | 28 | 18 | 10 | 0 | 0 | ||
Other gram-negative bacilli | 18–20 | 212 | 159 | 48 | 4 | 1 | 18 (I) | ||
Nitrofurantoin | Gram-negative bacilli and Staphylococcus sp. | 15–16 | 115 | 92 | 18 | 0 | 5 | 15 (I), 15 (I), 15 (I), 15 (I), 15 (I) | |
Norfloxacin | Gram-negative bacilli | 18–20 | 87 | 1 | 86 | 0 | 0 | ||
Oxacillin | Coagulase-negative staphylococci | ≥18 | 74 | 19 | 53 | 0 | 2 | 22 (S), 25 (S) | 2.7 |
S. aureus | 11–12 | 53 | 38 | 15 | 0 | 0 | |||
Penicillin G | Staphylococcus sp. | 28–29 | 127 | 115 | 12 | 0 | 0 | ||
Piperacillin | Pseudomonas sp. | ≥18 | 28 | 26 | 1 | 0 | 1 | 19 (S) | 3.6 |
Other gram-negative bacilli | 18–20 | 124 | 92 | 31 | 1 | 0 | |||
Trimethoprim-sulfamethoxazole | Gram-negative bacilli and Staphylococcus sp. | 11–15 | 366 | 266 | 96 | 2 | 2 | 16 (S), 12 (I) | 0.3 |
Vancomycin | Staphylococcus sp. | ≥15 | 127 | 127 | 0 | 0 | 0 |
Number of isolates susceptible or intermediate by both caliper and Sirscan.
Number of isolates resistant by both caliper and Sirscan.
Number of isolates susceptible or intermediate by caliper and resistant by Sirscan.
Number of isolates resistant by caliper and susceptible or intermediate by Sirscan.
S, sensitive; I, intermediate; R, resistant.
(Number of Rc/SIs isolates) − (number of intermediate isolates)/number of isolates tested × 100.